RxDoctor Payments Data

Forrest Yorgason, PA

Psychiatric/Mental Health · Springville, UTNPI 1932823572

Payments from drug & device makers

$1,296in general payments, 2019–2025

Across 81 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$184
  • Takeda Pharmaceuticals U.S.A., Inc.$177
  • AbbVie$173
  • Teva Pharmaceuticals USA, Inc.$135
  • Lundbeck LLC$133
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$104
  • plus $390 from 11 others

What the payments were for

  • Food & beverage$1,296100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,296 in reported general payments places this provider in the 70th percentile of 393 psychiatric/mental health providers in Utah.

See all psychiatric/mental health providers in Utah

Medicare billing

Part B allowed, 2024
$261,448
Medicare patients
359
Services billed
3,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4620$84,339
EliquisApixaban108$71,444
TrulicityDulaglutide20$20,017
OzempicSemaglutide14$16,007
Soliqua 100-33Insulin Glargine/Lixisenatide17$14,184
TrintellixVortioxetine Hydrobromide30$14,047
XareltoRivaroxaban20$12,143
Spiriva RespimatTiotropium Bromide19$10,413
EntrestoSacubitril/Valsartan14$10,132
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog41$7,267
JanuviaSitagliptin Phosphate13$7,236
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$6,617
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$5,178
Lamotrigine ErLamotrigine14$5,165
Levothyroxine Sodium400$4,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$177$14,04730 claims
Johnson & JohnsonXarelto$41$12,14320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 393 psychiatric/mental health providers in Utah.

Other psychiatric/mental health in Springville

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →